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LINEZOLID-ASSOCIATED THROMBOCYTOPENIA IN CHILDREN WITH RENAL IMPAIRMENT
Chad A. Knoderer, PharmD; Kristen R. Nichols, PharmD, BCPS; Heather L. DeYoung, PharmD;
Sara J. Jones, PharmD; Elaine G. Cox, MD, FAAP
Butler University College of Pharmacy and Health Sciences,
Riley Hospital for Children at Indiana University Health, and Indiana University School of Medicine, 
Indianapolis, Indiana
Background: Independent risk factors for linezolid-associated 
thrombocytopenia are identified in adults, although similar data is lacking in 
pediatric patients. End-stage renal disease, pretreatment disease severity
score, catheter-related infection, duration of linezolid therapy greater than or 
equal to 14 days, creatinine clearance less than 50mL/min/1.73m2, and 
respiratory tract infection have been associated with thrombocytopenia. The 
objectives of this study were to evaluate and compare the rate of linezolid-
associated thrombocytopenia in pediatric patients with and without renal
impairment.
Methods: This was a retrospective cohort study of patients less than 18 years 
who received linezolid between January 1, 2007 and March 31, 2012 and had 
a documented serum creatinine (SCr) and height. Patients’ electronic medical 
records were reviewed to capture demographic data, baseline serum 
creatinine, baseline platelet count, indication for linezolid therapy (including 
cultures and susceptibility data), dosing, and therapy duration. Renal 
impairment was defined as an estimated creatinine clearance (CrCl) less than 
60 mL/min/1.73m2.  Thrombocytopenia was defined as less than 100 x 103 
platelets/mm3 or ≥ 30% reduction from baseline.
Results: One hundred seventy children with a median (IQR) age of 9 (3 – 14) 
years were included, and 22% of these had baseline renal impairment. 
Thrombocytopenia occurred more frequently in patients with baseline renal 
impairment (57% vs. 21%, p < 0.05).  Baseline estimated CrCl 
(mL/min/1.73m2) was significantly lower in patients who developed 
thrombocytopenia (median [IQR]: 66 [39 – 125] vs. 99 [78 – 130], p = 0.004). 
Seventy-five percent of patients with a low baseline platelet count (<170,000 
platelets/mm3) at initiation experienced thrombocytopenia versus 12.1% of 
patients with normal to high baseline platelet count (p <0.05).
Conclusion: Linezolid-associated thrombocytopenia in this pediatric cohort 
was associated with renal impairment and low platelet values upon therapy 
initiation. These findings illustrate the need for a diligent risk-benefit 
assessment prior to the initiation of linezolid therapy for children.
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ABSTRACT
METHODS
STUDY OBJECTIVE
Design and Setting:
•Retrospective, single center cohort
•Academic, free-standing children’s hospital
Study Population:
•Patients less than 18 years of age who received 
linezolid between January 1, 2007 and March 31, 
2012
•Exclusion criteria:
• No retrievable SCr
• No height
Procedures:
•Demographic and clinical data extracted from 
medical records included:
• LZD indication, dosing, and duration
• SCr, platelet, and white blood cell values 
collected at baseline and through therapy 
course
• Concurrent thrombocytopenia-associated 
drugs and other known thrombocytopenia-
associated factors
Definitions:
•Thrombocytopenia (TCP): platelet value < 100 X 
103 platelets/mm3 or ≥ 30% reduction from 
baseline
•Baseline platelet categorization
• Low: < 170 X 103 platelets/mm3
• Within normal limits or above: ≥ 170 X 103
platelets/mm3
•Renal impairment: CrCl ≤ 60 mL/min/1.73m2 
• Calculated using Schwartz or Modified 
Schwartz equations
•Infection resolution:
• Afebrile at least 48 hours
• Documented clinical improvement
• Negative cultures
To evaluate and compare the rates of linezolid-
associated thrombocytopenia in pediatric patients 
with and without renal impairment
BACKGROUND
• Linezolid (LZD) is an alternative to vancomycin 
for treatment of methicillin-resistant 
Staphylococcus aureus and Vancomycin-
resistant Enterococcus faecium
• Pediatric pharmacokinetics1:
• Primary hepatic metabolism
• ~ 30% excreted as unchanged drug in 
urine
• Age-related changes in clearance
• Linezolid-associated thrombocytopenia (LAT) 
complicates therapy
• Pediatric incidence and related factors not 
well defined
Study Primary Finding
Lin (2006) LAT more frequent in patients with renal 
insufficiency (64.7% vs. 35.6%, p = 0.039)
Matsumoto
(2010)
Linezolid clearance and CrCl strongly correlated 
(r = 0.933, p < 0.01)
Takahashi (2011) CrCL < 50 ml/min independent risk factor for 
LAT (OR: 2.32; 95% CI: 1.45 – 3.74)
Nukui (2013) LAT more frequent in patients with GFR < 60 
ml/min (OR: 39.0; 95% CI: 3.8 – 399.8)
Table 1. Selected LAT findings from adult studies
METHODS RESULTS
Primary Outcomes:
• Primary: thrombocytopenia occurrence
• Secondary: infection resolution
Statistical Analysis:
• Independent samples t-test, chi-square analysis, 
and Mann-Whitney test for non-parametric data
• Study approved by the Institutional Review 
Board at Indiana University-Purdue University-
Indianapolis
RESULTS
• 170 children included
N = 170
Male 45.9%
Age [years]a 8.6 (3.1 – 13.8)
Weight [kg]a 26.5 (13.8 – 45.1)
Baseline SCr [mg/dL]a 0.51 (0.34 – 0.83) 
Baseline CrCl
[ml/min/1.73m2]a
103 (63.8 – 130)
LZD information
LZD dose 
[mg/kg/day]b
25.9 (6.6)
LZD duration [days]a 3 (1 – 7)
Enteral route 38.2%
Infectious Indications
Bacteremia 23.5%
SSTI or Osteoarticular 19.4%
CF exacerbation 16.5%
Other/Misc 13%
CNS 7.1%
HAP 5.9%
Febrile Neutropenia 5.3%
GI 3.5%
CAP 2.9%
Endocarditis 2.9%
Table 2. Baseline characteristics
a = Data reported as median (interquartile range [IQR}); b = data reported as 
mean (standard deviation [SD])
No TCP 
(n = 114)
TCP
(n = 47)
p-
value
Male 40.4% 56.3% 0.063
Age [years]a 8.8 (3.1 –
14.7)
6.4 (1.1 –
12.8) 
0.146
LZD Dose 
[mg/kg/day]b
25.6 (6.2) 26.6 (7.7) 0.444
LZD Duration 
[days]a
7 (3 – 11.3) 9 (4 – 21) < 0.05
Baseline CrCl
[ml/min/1.73m2] a
105 (78 –
130)
66 (39 –
125)
< 0.05
Baseline renal 
impairment
14% 43.8% < 0.05
Low baseline 
platelet
9.7% 70.2% < 0.05
TCP risk factors 96.5% 97.9% 0.632
Table 3. Characteristics in children with and without TCP
• Infection resolution occurred in 94% overall
• Renal impairment at LZD initiation present in 
22% overall
• TCP incidence evaluable in 161 patients
• Developed in 29.2% (n = 47) overall
a = Data reported as median (IQR); b = data reported as mean (SD)
CONCLUSIONS
• Overall 29% thrombocytopenia in children 
receiving LZD in this pediatric cohort
• LAT appears to be an important adverse effect in 
children and adults
• The following variables at LZD initiation may be 
related to pediatric LAT:
• Platelet value < 170 X 103 platelets/mm3
• CrCl
• CrCl ≤ 60mL/min/1.73m2
• An association between therapy duration and 
TCP was noted
• Close monitoring of renal function should be 
considered during LZD therapy
• Additional studies are needed to determine if 
dose modifications are warranted for children 
receiving LZD with renal impairment  
